MIBIOANDCMD

"Gut microbiota, choline metabolites and cardiometabolic diseases."

Coordinatore	TARTU ULIKOOL    more  Organization address address: ULIKOOLI 18 city: TARTU postcode: 50090 contact info Titolo: Prof. Nome: Andres Cognome: Metspalu Email: send email Telefono: +372 737 5066 Fax: 3727374060
Nazionalità Coordinatore	Estonia [EE]
Totale costo	248˙299 €
EC contributo	248˙299 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IOF
Funding Scheme	MC-IOF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2016-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TARTU ULIKOOL  Organization address address: ULIKOOLI 18 city: TARTU postcode: 50090 contact info Titolo: Prof. Nome: Andres Cognome: Metspalu Email: send email Telefono: +372 737 5066 Fax: 3727374060	EE (TARTU)	coordinator	248˙299.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Common forms of cardiovascular diseases are exceptionally complex, where several genetic and lifestyle/environmental factors are involved. The discovery of different risk factors will be crucial for prevention of these high mortality diseases. Metabolomic studies have broaden our understanding of cardiovascular phenotypes and have created possibility to find new biomarkers for disease risk prediction. Recently a targeted metabolomic study indentified a novel mechanism through which gut-flora and hepatic-mediated metabolism of dietary choline contributes to the development of cardiovascular disease. This study demonstrated that higher plasma levels of choline and two of its metabolites, trimethylamine N-oxide (TMAO) and betaine, are associated with atherosclerosis in humans and mice. The current proposal aims to study the role of choline metabolites in cardiovascular and metabolic traits and to examine microbial role in this process. The possible role of choline-derived metabolites in perturbation of cardiometabolic phenotypes will be determined using well-characterized metabolic and cardiovascular-targeted samples. The second part of the project aims to study the role of gut flora in choline metabolic pathway. We will use different approaches in order to identify specific group(s) of intestinal bacteria responsible for the formation of TMA(O) from dietary choline. In summary, the results of the study will provide important insights into the mechanism by which novel metabolite-gut flora interplay contributes to the regulation of cardiovascular system.'